Page 54 - Read Online

Sooi et al. Cancer Drug Resist 2023;6:656-73 https://dx.doi.org/10.20517/cdr.2023.48 Page 670

41. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med
2012;366:2443-54. DOI PubMed PMC
42. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment
with response to anti-PD-1 therapy. Clin Cancer Res 2014;20:5064-74. DOI PubMed PMC
43. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid
tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75. DOI PubMed
PMC
44. Martin AM, Nirschl TR, Nirschl CJ, et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
Prostate Cancer Prostatic Dis 2015;18:325-32. DOI PubMed PMC
45. Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215-28. DOI
46. Dias A, Kote-Jarai Z, Mikropoulos C, Eeles R. Prostate cancer germline variations and implications for screening and treatment. Cold
Spring Harb Perspect Med 2018;8:a030379. DOI PubMed PMC
47. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to
poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-15. DOI PubMed
48. Abida W, Campbell D, Patnaik A, et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor
rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study. Clin Cancer Res
2020;26:2487-96. DOI PubMed PMC
49. de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 2020;382:2091-102.
DOI PubMed
50. Fizazi K, Piulats JM, Reaume MN, et al. Rucaparib or physician’s choice in metastatic prostate cancer. N Engl J Med 2023;388:719-
32. DOI PubMed PMC
51. Clarke NW, Armstrong AJ, Thiery-vuillemin A, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer.
NEJM Evidence 2022;1:EVIDoa2200043. DOI
52. Shen J, Zhao W, Ju Z, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune
checkpoint blockade independent of BRCAness. Cancer Res 2019;79:311-9. DOI PubMed PMC
53. Pham MM, Ngoi NYL, Peng G, Tan DSP, Yap TA. Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy
combinations: progress, pitfalls, and promises. Trends Cancer 2021;7:958-70. DOI PubMed PMC
54. Karzai F, VanderWeele D, Madan RA, et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in
men with and without DNA damage repair mutations. J Immunother Cancer 2018;6:141. DOI PubMed PMC
55. Alva AS, Li J, Chou J, et al. Phase 2 trial of immunotherapy in tumors with CDK12 inactivation (IMPACT): results from cohort A of
patients (pts) with metastatic castration resistant prostate cancer (mCRPC) receiving dual immune checkpoint inhibition (ICI). J Clin
Oncol 2022;40:103. DOI
56. López-Campos F, Gajate P, Romero-Laorden N, et al. Immunotherapy in advanced prostate cancer: current knowledge and future
directions. Biomedicines 2022;10:537. DOI PubMed PMC
57. Movassaghi M, Chung R, Anderson CB, Stein M, Saenger Y, Faiena I. Overcoming immune resistance in prostate cancer: challenges
and advances. Cancers 2021;13:4757. DOI PubMed PMC
58. Prokhnevska N, Emerson DA, Kissick HT, Redmond WL. Immunological complexity of the prostate cancer microenvironment
influences the response to immunotherapy. Adv Exp Med Biol 2019;1210:121-47. DOI PubMed
59. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med
2010;363:411-22. DOI PubMed
60. Sheikh NA, Petrylak D, Kantoff PW, et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized
phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 2013;62:137-47. DOI PubMed
PMC
61. GuhaThakurta D, Sheikh NA, Fan LQ, et al. Humoral immune response against nontargeted tumor antigens after treatment with
sipuleucel-t and its association with improved clinical outcome. Clin Cancer Res 2015;21:3619-30. DOI PubMed PMC
62. Warren TL, Weiner GJ. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr Opin Hematol
2000;7:168-73. DOI PubMed
63. Simons JW, Carducci MA, Mikhak B, et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate
cancer. Clin Cancer Res 2006;12:3394-401. DOI PubMed
64. Rauch S, Jasny E, Schmidt KE, Petsch B. New vaccine technologies to combat outbreak situations. Front Immunol 2018;9:1963.
DOI PubMed PMC
65. Bouard D, Alazard-Dany N, Cosset FL. Viral vectors: from virology to transgene expression. Br J Pharmacol 2009;157:153-65. DOI
PubMed PMC
66. Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.
Expert Opin Investig Drugs 2009;18:1001-11. DOI PubMed PMC
67. Gulley JL, Borre M, Vogelzang NJ, et al. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic
castration-resistant prostate cancer. J Clin Oncol 2019;37:1051-61. DOI PubMed PMC
68. Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic
castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012;13:501-8. DOI PubMed PMC